Reason for request
Inclusion of the list of medicines reimbursed by National Insurance and approved for use by hospitals. .
Clinical Benefit
| Substantial |
The actual benefit of these drugs is substantial. |
Clinical Added Value
| minor |
INOVELON offers a minor (level IV) improvement in actual benefit in the therapeutic management of patients aged 4 and over with Lennox-Gastaut syndrome that is resistant to first-line treatments. |
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
psWyFGL4BjVBhfHd
